These effects were associated with the upregulation of Rb, p53, p21, and p27 and the downregulation of cyclin D1, cyclin E, CDK4, and phospho-Rb, which offer mechanistic insight for their further exploitation in HCC treatment [102]. The gene discussed is CDK4; the disease is hepatocellular carcinoma.